25.54
0.08%
-0.02
After Hours:
25.60
0.06
+0.23%
Protagonist Therapeutics Inc stock is currently priced at $25.54, with a 24-hour trading volume of 440.39K.
It has seen a -0.08% decreased in the last 24 hours and a -8.75% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $25.55 pivot point. If it approaches the $24.79 support level, significant changes may occur.
Previous Close:
$25.56
Open:
$25.74
24h Volume:
440.39K
Market Cap:
$1.50B
Revenue:
$45.48M
Net Income/Loss:
$-78.96M
P/E Ratio:
-9.5299
EPS:
-2.68
Net Cash Flow:
$-70.85M
1W Performance:
+3.57%
1M Performance:
-8.75%
6M Performance:
+65.74%
1Y Performance:
+7.63%
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Name
Protagonist Therapeutics Inc
Sector
Industry
Phone
510 474 0170
Address
7707 Gateway Boulevard, Suite 140, Newark, CA
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-25-23 | Resumed | Jefferies | Buy |
Aug-25-22 | Initiated | JMP Securities | Mkt Outperform |
Feb-11-22 | Initiated | BTIG Research | Buy |
Oct-12-21 | Upgrade | JP Morgan | Neutral → Overweight |
Oct-11-21 | Upgrade | Northland Capital | Market Perform → Outperform |
Sep-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
May-24-21 | Initiated | JMP Securities | Mkt Outperform |
May-24-21 | Initiated | Northland Capital | Outperform |
Jan-06-21 | Initiated | JP Morgan | Overweight |
Dec-16-20 | Initiated | Piper Sandler | Overweight |
Sep-18-20 | Reiterated | H.C. Wainwright | Buy |
Jul-15-20 | Initiated | Jefferies | Buy |
May-18-20 | Reiterated | H.C. Wainwright | Buy |
Jul-08-19 | Initiated | H.C. Wainwright | Buy |
May-09-19 | Upgrade | Stifel | Hold → Buy |
Dec-06-18 | Initiated | Nomura | Buy |
Jan-29-18 | Initiated | Stifel | Buy |
Jul-21-17 | Initiated | BTIG Research | Buy |
View All
Protagonist Therapeutics Inc Stock (PTGX) Latest News
All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy
Zacks Investment Research
Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet
Zacks Investment Research
4 Stocks to Buy for Attractive Earnings Acceleration
Zacks Investment Research
Zacks.com featured highlights Protagonist Therapeutics, AxoGen, Western Digital and Phunware
Zacks Investment Research
4 Must-Buy Stocks for Remarkable Earnings Acceleration
Zacks Investment Research
Earnings Estimates Moving Higher for Protagonist Therapeutics (PTGX): Time to Buy?
Zacks Investment Research
Protagonist Therapeutics Inc Stock (PTGX) Financials Data
Protagonist Therapeutics Inc (PTGX) Revenue 2024
PTGX reported a revenue (TTM) of $45.48 million for the quarter ending June 30, 2022, a +67.11% rise year-over-year.
Protagonist Therapeutics Inc (PTGX) Net Income 2024
PTGX net income (TTM) was -$78.95 million for the quarter ending December 31, 2023, a +38.02% increase year-over-year.
Protagonist Therapeutics Inc (PTGX) Cash Flow 2024
PTGX recorded a free cash flow (TTM) of -$70.84 million for the quarter ending December 31, 2023, a +34.96% increase year-over-year.
Protagonist Therapeutics Inc (PTGX) Earnings per Share 2024
PTGX earnings per share (TTM) was -$1.49 for the quarter ending December 31, 2023, a +42.69% growth year-over-year.
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis. It is also developing an oral peptide targeting a GI condition other than IBD. The company was founded in 2006 and is headquartered in Newark, California.
Cap:
|
Volume (24h):